Urapidil is a α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist. Urapidil does not affect vascular tone at concentrations up to 10-5 M. Urapidil (10-5 M) markedly inhibits the alpha 1-adrenergic agonist (phenylephrine)-induced concentration-dependent contractions in aortic rings without endothelium and also to some extent in those with endothelium. Moreover, the inhibitory effect of Urapidil is more pronounced in rings without endothelium than in those with endothelium[3]. It has an alpha 1-blocking action, a weak beta 1-blocking effect, an interaction with a serotonin receptor and a central depression of sympathetic tone. Urapidil is well absorbed orally with a bioavailability of about 70% and a time to peak concentration of about 4 hours after a sustained release capsule. It is metabolized in the liver at a half-life of 4.7 hours. Urapidil does not inhibit the exercise increase in heart rate[4]. Urapidil has also been shown to improve glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia[5]. Urapidil, in contrast to nicardipine and clevidipine, preserves the hypoxia-triggered vasoconstriction in isolated pulmonary arteries[6].
Australia, New South Wales
... 展开 >>
Concord Hospital
Concord, New South Wales, Australia, 2138
Gosford Hospital
Gosford, New South Wales, Australia, 2250
St George Hospital
Kogarah, New South Wales, Australia, 2217
John Hunter Hospital
Newcastle, New South Wales, Australia, 2310
St Vincent's Hospital
Sydney, New South Wales, Australia, 2010
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia, 2050
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Royal Melbourne Hospital
Melbourne, Victoria, Australia, 3050
St Vincent's Hospital
Melbourne, Victoria, Australia, 3065
Box Hill Hospital
Melbourne, Victoria, Australia, 3128
Alfred Hospital
Melbourne, Victoria, Australia, 3181
Austin Health
Melbourne, Victoria, Australia
Monash Medical Centre
Melbourne, Victoria, Australia
Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
China
Regional Coordinating Centre: Peking University First Hospital
Beijing, China, 100034
Hospitals in China, c/o The George Institute China
Beijing, China
Regional Coordinating Centre: Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Second Medical University
Shanghai, China, 200025
New Zealand
North Shore Hospital
Auckland, New Zealand
Christchurch Hospital
Christchurch, New Zealand 收起 <<
Ischemic Stroke
... 展开 >> High Blood Pressure 收起 <<
Phase 3
Recruiting
February 2019
Australia, New South Wales
... 展开 >>
Royal Prince Alfred Hospital
Recruiting
Sydney, New South Wales, Australia, 2050
Contact: Craig S Anderson, MD +61 2 933 4500 canderson@georgeinstitute.org.au 收起 <<
China, Guangdong
... 展开 >>
the First Affiliated Hospital of Sun Yetsen University
Recruiting
Guangzhou, Guangdong, China, 510080
Contact: Yi Liu, Master +86 13632391455 liuyisysu@126.com
Contact: Nan Jiang, professor +86 20 28823350 NJiang_sysu@126.com 收起 <<
France
... 展开 >> Service d'Anesthésie - CMCO
Not yet recruiting
Schiltigheim, France, 67303
Contact: Pierre DIEMUNSCH, MD.PH
Sub-Investigator: Rita VIZITIU, MD
Sub-Investigator: Valentina FAITOT, MD
Service d'Anesthésie et de Réanimation Médicale, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg
Recruiting
Strasbourg, France, 67098
Contact: Pierre DIMUNSCH, PUPH 33.3.88.12.70.78 pierre.diemunsch@chru-strasbourg.fr
Principal Investigator: Pierre DIEMUNSCH, PUPH
Sub-Investigator: Vincent GARCIA, CCU 收起 <<
搜索
